Program of the conference

Strona tytułowa programu
Platelets and Coronary Interventions
Bydgoszcz, Opera Nova, 21-22.06.2013
Program of the conference
The conference is organized under the auspices of
Professor Andrzej Tretyn
Rector of Nicolaus Copernicus University
Professor Janina Stępińska
President of The Polish Society of Cardiology
Doctor Jacek Janiszewski
President of The Program Board of
Association of Integration and Cooperation
Tomasz Pietraszak
Chief Executive of The Regional Branch of Polish Television in Bydgoszcz
Michał Jagodziński
Editor-in-Chief
Polish Radio PiK
Program of the conference "Platelets and Coronary Interventions"
Friday, 21st June 2013
11.00-11.15 Opening
11.15-11.30 Andreas Vesalius: a true Renaissance man. Michał Szpinda (Bydgoszcz, Poland)
Session: Application of basic science to optimize antithrombotic treatment
Chairpersons: Tobias Geisler (Tübingen, Germany), Udaya Tantry (Baltimore, US)
11.30-11.50 A new simple to use approach to monitoring platelet function for long-term
treatment with antiplatelet agents. Stan Heptinstall (Nottingham, UK)
11.50-12.10 Platelet-fibrin clot strength and viscosity: clinical implication and treatment.
Young-Hoon Jeong (Jinju, South Korea)
12.10-12.30 Antiplatelet therapy during increased platelet turnover. Grzegorz Grześk
(Bydgoszcz, Poland)
12.30-12.50 Do we need a short-acting, potent P2Y12 inhibitor? Marek Koziński (Bydgoszcz,
Poland)
12.50-13.30 Discussion
13.30-15.00 Lunch
Session: Antithrombotic treatment beyond DAPT after ACS
Chairpersons: Young-Hoon Jeong (Jinju, South Korea), Stan Heptinstall (Nottingham, UK)
15.00-15.20 Thrombin PAR-1 receptor as a potential therapeutic target. Tobias Geisler
(Tübingen, Germany)
15.20-15.40 Antiplatelet therapy in patients on the new oral anticoagulants. Freek
Verheugt (Amsterdam, the Netherlands)
15.40-16.00 Low-dose of oral factor X inhibitors in patients with a recent acute coronary
syndrome: a systematic review and meta-analysis of randomized trials. Karolina Obońska
(Bydgoszcz, Poland)
16.00-16.30 Discussion
19.00 Opening dinner
Saturday, 22nd June 2013
Session: Optimal antiplatelet therapy with P2Y12 inhibitors
Chairpersons: Jacek Kubica (Bydgoszcz, Poland), Jolanta Siller-Matula (Vienna, Austria)
9.00-9.20 High-dose clopidogrel versus prasugrel in patients with high on-clopidogrel platelet
reactivity. Daniel Aradi (Pecs, Hungary)
9.20-9.40 Variability in response to the new anti-platelet drugs prasugrel and ticagrelor: is it a
real problem with clinical significance? Eli Lev (Petah-Tikva, Israel)
9.40-10.00 Personalized antiplatelet therapy: presence and future. Udaya Tantry (Baltimore,
US)
10.00-10.30 Discussion
Session: Percutaneous coronary interventions
Chairpersons: Daniel Aradi (Pecs, Hungary), Eliano Pio Navarese (Bydgoszcz, Poland)
10.30-10.50 Does stent design affect thrombosis? Wojciech Wojakowski (Katowice, Poland)
10.50-11.10 High on-treatment platelet reactivity and other risk factors of ischemic events
after implantation of drug-eluting stents. Long-term follow-up of 300 patients. Maciej Lesiak
(Poznań, Poland)
11.10-11.30 Is it time to forget about clopidogrel? Rober Gil (Warszawa, Poland)
11.30-12.00 Discussion
12.00-13.00 Lunch
Session: Advances in acute coronary syndromes
Chairpersons: Andrzej Budaj (Warszawa, Poland), Rober Gil (Warszawa, Poland)
13.00-13.20 How to start fast and appropriate antiplatelet treatment in emergency department
in ACS patients? Salvadore Di Somma (Rome, Italy)
13.20-13.40 Drug-eluting stents in acute myocardial infarction – a case of off-label use?
Miłosz Jaguszewski
13.40-14.00 Optimal timing of coronary invasive strategy in patients with acute coronary
syndromes without ST-segment elevation. Eliano Pio Navarese (Bydgoszcz, Poland)
14.00-14.20 No-reflow phenomenon and platelets. Wiktor Kuliczkowski (Zabrze, Poland)
14.20-14.50 Discussion
14.50-15.00 Coffee break
Session: How to improve clinical outcomes? Focus on the balance between ischaemic
and bleeding complications.
Chairpersons: Maciej Lesiak (Poznań, Poland), Eli Lev (Petah-Tikva, Israel),
15.00-15.20 Mortality benefit of antithrombotic and antiplatelet agents in acute coronary
syndromes. Andrzej Budaj (Warszawa, Poland)
15.20-15.40 Antithrombotic therapy in PCI patients with indication for oral anticoagulation.
Jolanta Siller-Matula (Vienna, Austria)
15.40-16.00 Antithrombotic treatment in heart failure. Marcin Gruchała (Gdańsk, Poland)
16.00-16.30 Discussion